187 related articles for article (PubMed ID: 30007103)
1. Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Morita Y; Maeda Y; Yamaguchi T; Urase F; Kawata S; Hanamoto H; Tsubaki K; Ishikawa J; Shibayama H; Matsumura I; Matsuda M
Cancer Sci; 2018 Oct; 109(10):3209-3215. PubMed ID: 30007103
[TBL] [Abstract][Full Text] [Related]
2. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
Fujimaki K; Miyashita K; Kawasaki R; Tomita N
Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
[TBL] [Abstract][Full Text] [Related]
4. Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial.
Park S; Park SY; Lee JH; Choi EJ; Lee KH; Yoon SS; Hong J; Shin DY; Kim YJ
Cancer; 2022 Dec; 128(23):4095-4108. PubMed ID: 36208097
[TBL] [Abstract][Full Text] [Related]
5. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
[TBL] [Abstract][Full Text] [Related]
7. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
[TBL] [Abstract][Full Text] [Related]
8. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Zeidan AM; Borate U; Pollyea DA; Brunner AM; Roncolato F; Garcia JS; Filshie R; Odenike O; Watson AM; Krishnadasan R; Bajel A; Naqvi K; Zha J; Cheng WH; Zhou Y; Hoffman D; Harb JG; Potluri J; Garcia-Manero G
Am J Hematol; 2023 Feb; 98(2):272-281. PubMed ID: 36309981
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
10. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Ljung T; Bäck R; Hellström-Lindberg E
Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.
Sanchez-Garcia J; Falantes J; Medina Perez A; Hernandez-Mohedo F; Hermosin L; Torres-Sabariego A; Bailen A; Hernandez-Sanchez JM; Solé Rodriguez M; Casaño FJ; Calderon C; Labrador M; Vahí M; Serrano J; Lumbreras E; Hernández-Rivas JM;
Leuk Lymphoma; 2018 May; 59(5):1095-1104. PubMed ID: 28836866
[TBL] [Abstract][Full Text] [Related]
12. Refractory anemia with ring sideroblasts associated with marked thrombocytosis harboring cytogenetic abnormality dup(2)(p15p22) treated with decitabine.
Kim J; Kim YR; Lee KA
Leuk Lymphoma; 2012 Nov; 53(11):2287-9. PubMed ID: 22468921
[No Abstract] [Full Text] [Related]
13. Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.
Du X; Lai YY; Xiao Z; Liu T; Hu Y; Sun A; Li X; Shen ZX; Jin J; Yu L; Laille E; Dong Q; Songer S; Beach CL
Asia Pac J Clin Oncol; 2018 Jun; 14(3):270-278. PubMed ID: 29282890
[TBL] [Abstract][Full Text] [Related]
14. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
[TBL] [Abstract][Full Text] [Related]
15. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
[TBL] [Abstract][Full Text] [Related]
17. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
Garcia-Manero G; Gore SD; Kambhampati S; Scott B; Tefferi A; Cogle CR; Edenfield WJ; Hetzer J; Kumar K; Laille E; Shi T; MacBeth KJ; Skikne B
Leukemia; 2016 Apr; 30(4):889-96. PubMed ID: 26442612
[TBL] [Abstract][Full Text] [Related]
20. Treatment of myelodysplastic syndrome with cyclosporin A.
Chen S; Jiang B; Da W; Gong M; Guan M
Int J Hematol; 2007 Jan; 85(1):11-7. PubMed ID: 17261496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]